BioSyent logo.png
FeraMAX(MD) est le 1er choix de supplément de fer recommandé par les pharmaciens et les médecins canadiens pour la sixième année consécutive
May 05, 2021 08:42 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 05 mai 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que pour la sixième année consécutive, FeraMAXMD a été...
BioSyent logo.png
FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Sixth Consecutive Year
May 03, 2021 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 03, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the sixth consecutive year, FeraMAX® has been named the #1...
BioSyent logo.png
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2021 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 14, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co....
BioSyent logo.png
BioSyent Announces Grant of Restricted Share Units
March 19, 2021 17:33 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted...
BioSyent logo.png
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020
March 17, 2021 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 17, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020. Key...
BioSyent logo.png
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021
March 11, 2021 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available
December 16, 2020 09:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent logo.png
BioSyent Announces Renewal of Normal Course Issuer Bid
December 11, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent logo.png
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
November 26, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key...
BioSyent logo.png
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
November 17, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...